Clinical Application of Serologic Testing for Coronavirus Disease 2019 in Contemporary Cardiovascular Practice

Abdulla A Damluji, Robert H Christenson, Christopher deFilippi, Abdulla A Damluji, Robert H Christenson, Christopher deFilippi

Abstract

In patients with cardiovascular disease, the use of antibody or serological testing is frequently encountered as the coronavirus disease 2019 pandemic continues to evolve. Antibody testing detects one form of the acquired immunological response to a pathogenic antigen. Once the immune system recognizes a viral antigen or a protein as foreign, a humoral immune response is initiated, which is generally detected by laboratory testing in 5 to 10 days after the initial exposure. While this information is critical from a public health perspective to implement surveillance systems and measures to limit infectivity and transmission rate, the misinterpretation of serologic testing in clinical practice has generated much confusion in the medical community because some attempted to apply these strategies to individual patient's treatment schemes. In this mini-review, we examine the different serologic-based testing strategies, how to interpret their results, and their public health impact at the population level, which are critical to contain the transmission of the virus in the community within a busy cardiovascular practice. Further, this review will also be particularly helpful as vaccination and immune therapy for coronavirus disease 2019 become available to the society as a whole.

Keywords: COVID‐19; cardiovascular diseases; immunity; serologic test.

Conflict of interest statement

Dr Christenson discloses honoraria, consulting, and scientific advisory board participation with Siemens Healthineers, Roche Diagnostic (and Medscape), Beckman‐Coulter, PixCell, Quidel Corporation, BD Diagnostics and Sphingotec. Dr Christenson receives research funding from Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, Beckman‐Coulter, Mitsubushi, Abbott Diagnostics, Quidel Corporation, Becton Dickinson, Sphingotech (NexusDx), Ortho Clinical Diagnostics and PixCell. Dr deFilippi reports consulting fees from Abbott Diagnostics, FujiRebio, Quidel, Ortho Diagnostics, Roche Diagnostics, and Siemens Healthineers. Dr Damluji has no disclosures to report.

Figures

Figure 1. Serology‐based testing to SARS‐COV‐2.
Figure 1. Serology‐based testing to SARS‐COV‐2.
The figure illustrates the protein antigens of the severe acute respiratory syndrome coronavirus 2: nucleocapsid phosphoprotein, spike full‐length protein, and receptor binding domain and the 2 most common serology‐based testing strategies: enzyme‐linked immunosorbent assay and chemiluminescent immunoassay. PRNT50 indicates 50% plaque reduction neutralization test; and SARS‐COV‐2, severe acute respiratory syndrome coronavirus 2. The nucleocapsid protein is not shown in the illustration because it is attached to the viral RNA. The illustration only shows the surface proteins; the orange proteins represent the phospholipid bilayer. The blue/purple 5‐part proteins represent viroporin pentamers, also called E proteins.
Figure 2. Positive predictive value for 2…
Figure 2. Positive predictive value for 2 testing strategies by prevalence of COVID‐19 in a hypothetical situation.
COVID‐19 indicates coronavirus disease 2019. Data derived from https://www.cdc.gov/coronavirus/2019‐ncov/lab/resources/antibody‐tests‐guidelines.html/.

References

    1. Peeling RW, Wedderburn CJ, Garcia PJ, Boeras D, Fongwen N, Nkengasong J, Sall A, Tanuri A, Heymann DL. Serology testing in the covid‐19 pandemic response. Lancet Infect Dis. 2020;20:e245–e249. DOI: 10.1016/S1473-3099(20)30517-X.
    1. Long Q‐X, Tang X‐J, Shi Q‐L, Li Q, Deng H‐J, Yuan J, Hu J‐L, Xu W, Zhang Y, Lv F‐J, et al. Clinical and immunological assessment of asymptomatic SARS‐CoV‐2 infections. Nat Med. 2020;26:1200–1204. DOI: 10.1038/s41591-020-0965-6.
    1. Petherick A. Developing antibody tests for SARS‐CoV‐2. Lancet. 2020;395:1101–1102. DOI: 10.1016/S0140-6736(20)30788-1.
    1. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Characterization of the receptor‐binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17:613–620. DOI: 10.1038/s41423-020-0400-4.
    1. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Hayford K, Luquero FJ, Mina MJ, Rodriguez‐Barraquer I, et al. Serology for SARS‐CoV‐2: apprehensions, opportunities, and the path forward. Sci Immunol. 2020;5:eabc6347. DOI: 10.1126/sciimmunol.abc6347.
    1. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L‐P, Johnston JC, Lan Z, Law S, MacLean E, Trajman A, et al. Diagnostic accuracy of serological tests for covid‐19: systematic review and meta‐analysis. BMJ. 2020;370:m2516. DOI: 10.1136/bmj.m2516.
    1. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, et al. A serological assay to detect SARS‐CoV‐2 seroconversion in humans. Nat Med. 2020;26:1033–1036. DOI: 10.1038/s41591-020-0913-5.
    1. Current Status of Antibody Testing in the United States. Available at: . Accessed January 21, 2021.
    1. Interim Guidance for Use of Pooling Procedures in SARS‐CoV‐2 Diagnostic, Screening, and Surveillance Testing. Available at: . Accessed January 21, 2021.
    1. Introduction to Public Health Surveillance. Available at: . Accessed January 21, 2021.
    1. Steensels D, Oris E, Coninx L, Nuyens D, Delforge ML, Vermeersch P, Heylen L. Hospital‐wide SARS‐CoV‐2 antibody screening in 3056 staff in a tertiary center in Belgium. JAMA. 2020;324:195–197. DOI: 10.1001/jama.2020.11160.
    1. Wang Y, Zhang LU, Sang L, Ye F, Ruan S, Zhong B, Song T, Alshukairi AN, Chen R, Zhang Z, et al. Kinetics of viral load and antibody response in relation to COVID‐19 severity. J Clin Invest. 2020;130:5235–5244. DOI: 10.1172/JCI138759.
    1. Wajnberg A, Amanat F, Firpo A, Altman D, Bailey M, Mansour M, McMahon M, Meade P, Mendu DR, Muellers K, et al. SARS‐CoV‐2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv. 2007:2020.2007.2014.20151126.
    1. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PM, Thouvenel C, Takehara KK, Eggenberger J, Hemann EA, Waterman HR, et al. Functional SARS‐CoV‐2‐specific immune memory persists after mild COVID‐19. medRxiv. 2020:2020.2008.2011.20171843.
    1. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, Arnthorsson AO, Helgason D, Bjarnadottir K, Ingvarsson RF, et al. Humoral immune response to SARS‐CoV‐2 in Iceland. N Engl J Med. 2020;383:1724–1734. DOI: 10.1056/NEJMoa2026116.
    1. Patel MM, Thornburg NJ, Stubblefield WB, Talbot HK, Coughlin MM, Feldstein LR, Self WH. Change in antibodies to SARS‐CoV‐2 over 60 days among health care personnel in Nashville, Tennessee. JAMA. 2020;324:1781–1782. DOI: 10.1001/jama.2020.18796.
    1. Ibarrondo FJ, Fulcher JA, Goodman‐Meza D, Elliott J, Hofmann C, Hausner MA, Ferbas KG, Tobin NH, Aldrovandi GM, Yang OO. Rapid decay of anti–SARS‐CoV‐2 antibodies in persons with mild Covid‐19. N Engl J Med. 2020;383:1085–1087.
    1. Loss of anti–SARS‐CoV‐2 antibodies in mild Covid‐19. N Engl J Med. 2020;383:1697–1698. DOI: 10.1056/NEJMc2027051.
    1. Premkumar L, Segovia‐Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L, Weiss S, Park Y, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS‐CoV‐2 patients. Sci Immunol. 2020;5:eabc8413. DOI: 10.1126/sciimmunol.abc8413.
    1. Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, Yang X, Wang B, Chen L, Chen Q, et al. SARS‐CoV‐2 infection induces sustained humoral immune responses in convalescent patients following symptomatic covid‐19. medRxiv. 2020:2020.2007.2021.20159178.
    1. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, Thompson MR, Bradshaw C, Weinkauf CC, Bime C, et al. Orthogonal SARS‐CoV‐2 serological assays enable surveillance of low‐prevalence communities and reveal durable humoral immunity. Immunity. 2020;53:925–933.e924. DOI: 10.1016/j.immuni.2020.10.004.
    1. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P, Mendu DR, Muellers K, et al. Robust neutralizing antibodies to SARS‐CoV‐2 infection persist for months. Science. 2020;370:1227–1230. DOI: 10.1126/science.abd7728.
    1. Ladhani SN, Jeffery‐Smith A, Patel M, Janarthanan R, Fok J, Crawley‐Boevey E, Vusirikala A, Fernandez Ruiz De Olano E, Perez MS, Tang S, et al. High prevalence of SARS‐CoV‐2 antibodies in care homes affected by COVID‐19: prospective cohort study, England. EClinicalMedicine. 2020;28:100597. DOI: 10.1016/j.eclinm.2020.100597.
    1. Dan JM, Mateus J, Kato Y, Hastie KM, Faliti C, Ramirez SI, Frazier A, Yu ED, Grifoni A, Rawlings SA, et al. Immunological memory to SARS‐CoV‐2 assessed for greater than six months after infection. bioRxiv. 2020:2020.2011.2015.383323.
    1. Dan JM, Mateus J, Kato YU, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, et al. Immunological memory to SARS‐CoV‐2 assessed for up to 8 months after infection. Science. 2021:eabf4063. DOI: 10.1126/science.abf4063.
    1. Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA‐based Covid‐19 vaccine candidates. N Engl J Med. 2020;383:2439–2450. DOI: 10.1056/NEJMoa2027906.
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383:2603–2615. DOI: 10.1056/NEJMoa2034577.
    1. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Safety and immunogenicity of SARS‐CoV‐2 mRNA‐1273 vaccine in older adults. N Engl J Med. 2020;383:2427–2438. DOI: 10.1056/NEJMoa2028436.
    1. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, et al. REGN‐COV2, a neutralizing antibody cocktail, in outpatients with Covid‐19. N Engl J Med. 2021;384:238–251. DOI: 10.1056/NEJMoa2035002.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera